MAY 27·SEC EDGARLow
Thomas John Charles sold $194K of KRYS
Thomas John Charles (EVP, General Counsel) sold 642 shares of Krystal Biotech, Inc. (KRYS) at $302.03 ($0.19M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
StockHealthcare · Biotechnology
$KRYS
Krystal Biotech, Inc.
Price · $KRYSvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Top stories · $KRYSMore →
APR 29·MSN
Krystal Biotech, Inc. (KRYS) earnings expected to grow: What to know ahead of next week's release
This article focuses on Krystal Biotech, Inc. (KRYS) and the upcoming earnings report. It likely discusses analyst expectations for revenue and EPS growth, and possibly factors influencing these forecasts. Investors would be interested in the potential impact on KRYS's stock performance.
MAR 7·MarketBeat
Krystal Biotech (NASDAQ:KRYS) Insider Sells $6,580,250.00 in Stock
Suma Krishnan, an insider at Krystal Biotech (NASDAQ:KRYS), sold 25,000 shares of the company's stock for $6,580,250 on March 4th, reducing her ownership by 1.75%. This transaction comes after Krystal Biotech reported strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $326.25. The stock experienced a slight dip of 2.6% to $253.69 following the sale.